Warning lights
Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.
-
Tight liquidity NBB
Cash and receivables cover 44 % of short-term debt in 2026; threshold 65 %.
-
Busy address KBO
23 other companies have their registered office at the same address; threshold 10.
Financials
Financial year 2026
M.D.D. PHARMA from Wavre, company number BE0437759119, closed financial year 2026 with a result of € 370,209 after tax. For that financial year M.D.D. PHARMA recorded revenue of € 28.6 million and equity of € 565,871. Compared with financial year 2025, the result moved from € 823,861 to € 370,209. The company is profitable. The buffer is growing. High debts against a small own buffer. The most recent annual accounts were filed with the National Bank of Belgium on June 25, 2026.
€ 565,871
▲ 189% vs 2025
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ 370,209
▼ 55% vs 2025
Profit after tax over the fiscal year.
€ 19,800
▲ 33% vs 2025
Cash and bank balances on the last day of the fiscal year.
Stays in the company
No dividend for 2026. Retained profit grew to € 443,871.
People and assets in 2026
104.8
▼ 3.5 vs 2025
Average over the fiscal year, from the social balance sheet.
€ 5.5 million
▼ 1% vs 2025
€ 52,000 per full-time equivalent. Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.
€ 196,136
▲ 13% vs 2025
Book value of vehicles, furniture and equipment.
Debts at end 2026
€ 5.3 million
▼ 6% vs 2025
Loans from banks and other lenders, long and short.
€ 5 million
▲ 65% vs 2025
Supplier invoices still open on the last day of the fiscal year. Pays suppliers within 80 days on average.
€ 1 million
▼ 21% vs 2025
Taxes, VAT and social contributions still to pay.
Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →
| 2024 | 2025 | 2026 | Change 2025 → 2026 | |
|---|---|---|---|---|
| Revenue | € 17,787,715 | € 24,801,656 | € 28,623,047 | ▲ 15% |
| Profit after taxes | € 709,334 | € 823,861 | € 370,209 | ▼ 55% |
| Equity | € 521,801 | € 195,662 | € 565,871 | ▲ 189% |
| Total debts | € 8,619,819 | € 11,057,722 | € 11,286,433 | ▲ 2% |
| Cash | € 46,623 | € 14,919 | € 19,800 | ▲ 33% |
| Land & buildings | € 1,193,383 | € 1,712,049 | € 2,588,163 | ▲ 51% |
| Retained profit | € 399,801 | € 73,662 | € 443,871 | ▲ € 370,209 |
| Dividend | € 700,000 | € 1,150,000 | € 0 | ▼ 100% |
| Bank debt | € 5,043,708 | € 5,576,643 | € 5,269,322 | ▼ 6% |
| Balance sheet total | € 9,141,620 | € 11,253,384 | € 12,191,921 | ▲ 8% |
| Employees (FTE) | 99.6 | 108.3 | 104.8 | ▼ 3.5 |
Key figures of M.D.D. PHARMA, fiscal years 2024 to 2026, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2027) expected before 31 August 2027.
What happened to M.D.D. PHARMA?
What happened at M.D.D. PHARMA in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- New annual accounts for financial year 2026: profit of € 370,209 (▼ 55% vs 2025). Source: NBB ↗
- Philippe Lacroix stepped down as director. NBB
- Eveline Maryns stepped down as director. NBB
- Arnaud Berken stepped down as director. NBB
- Philippe Lacroix became a director. NBB
- Eveline Maryns became a director. NBB
- Arnaud Berken became a director. NBB
- New establishment in Kortrijk. KBO
In short
From € 709,334 profit in 2024 to € 370,209 profit in 2026.
Paid € 966,194 in corporate taxes since 2024.
Best year ever: 2025, with € 823,861 profit.
Paid out € 1.9 million in dividends to the owners in total.
A new publication or filing at M.D.D. PHARMA? We notify you, reason included.
Follow M.D.D. PHARMADatabakkes Pro
Know what changes at your customers, suppliers and competitors. Without reading an annual account.
- Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
- We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
- In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.
Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.
De Lijn 8 June 2026 New annual account 2025
filed on 8 June 2026
What was left
€ 20 k ▼ 91%
Money in the bank
€ 178 k ▼ 98%
Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit
Management
Directors
According to the 2026 annual accounts
Philippe Lacroix
Director
since 2023 · until 2026
Eveline Maryns
Director
since 2023 · until 2026
Arnaud Berken
Director
since 2023 · until 2026
Shareholders
100%
Participations
No participations in other companies reported.
Establishments
Establishment units
Physical locations of this company
Avenue Pasteur 2
1300 Wavre
Zwevegemsestraat(Kor) 38
8500 Kortrijk
Active since 27 September 1989
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 23 companies are registered at this address.
All companies at this address →VAQUAFERRA
€ -58,200 gross margin · 2021
BENU same network
€ 172.2 million revenue · 2026
CENTRE RX DE WAVRE
€ 557,316 gross margin · 2025
IMMO X
€ 119,688 gross margin · 2025
BENU Management
€ 9.5 million revenue · 2026
+18 more
What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 0437.759.119
- VAT number
- BE 0437.759.119
- Registered office
- Avenue Pasteur 2, 1300 Wavre
- Names & denominations
- M.D.D. PHARMA
- Enterprise type
- Rechtspersoon
- Legal form
- Public limited company
- Legal situation
- Normale toestand
- Start date
- 6 July 1989
- Peppol
- Active · Active since 10 Jun 2025
- Activities · NACE
Detailhandel in farmaceutische producten
Apothekers